Close Menu

Aperiomics: Alexander Valencia

Aug 15, 2019

Alexander Valencia has joined Aperiomics as Chief Clinical Officer. He will oversee the microorganism sequencing firm's clinical test development, validations, regulatory affairs, and operations.

Prior to joining Aperiomics, Valencia served as molecular laboratory director at Cincinnati Children's Hospital Medical Center. He has experience at PerkinElmer Genomics. He holds a doctorate from Canada's Carleton University and the University of Ottawa and held post-doctoral positions in biochemistry and molecular biology at the University of North Carolina at Chapel Hill and in clinical molecular genetics at Emory University.

More Like This

Jan 28, 2020

Interpace Biosciences: Fortunao Ron Rocca, Felice Schnoll-Sussman

Interpace Biosciences has appointed Fortunato Ron Rocca as a class II director.  Rocca will serve on the firm's board as a non-employee director. Concurrently with the appointment, Felice Schnoll-Sussman has resigned from Interpace Bio's board. Rocca currently serves as president and CEO of Exagen.

Jan 28, 2020

Personal Genome Diagnostics: Megan Bailey

Personal Genome Diagnostics has appointed Megan Baiely as chief commercial officer. Bailey previously joined the firm as VP of marketing in 2018. Prior to PGDx, Bailey spent more than 14 years at Roche in various sales and marketing roles, most recently as senior director of commercial operations. 

Jan 27, 2020

BioSoft Integrators: Debbie Bowers

BioSoft Integrators, a provider of informatics solutions for life science research and clinical diagnostic laboratories, has appointed Debbie Bowers as president and chief commercial officer. Bowers joined BioSoft as vice president of commercial operations in November 2017. Prior to joining BioSoft, she was VP of robotic operations at Hamilton Robotics. Prior to that, she was a VP of business development at Invetech, a then Danaher company that provides development and contract manufacturing services to global research, clinical, and consumer companies.

Jan 27, 2020

Biocartis: Ewoud Welten

Biocartis announced that CFO Ewoud Welten has decided to resign from the firm to pursue an opportunity in the Netherlands. Having served at Biocartis for about five years, Welten will stay with the firm until April. Biocartis has begun a selection process to recruit a new CFO

Jan 27, 2020

QuantuMDx: Jonathan O'Halloran, Neil Butler, Elaine Warburton, John Burn

QuantuMDx announced the appointments of Jonathan O'Halloran as CEO and Neil Butler as chairman of the board as the company begins its transition to commercialization.

A cofounder and former CSO of the firm, O'Halloran invented many of its proprietary technologies. He has a background in genetics and genomics and has been focusing on tuberculosis and antimicrobial resistance for the past 12 years.

QuantuMDx appointed Neil Butler to its board as a non-executive director in July 2019. He also serves on the boards of Nidor Dx, Radisens, and Spectromics and previously served as chair and non-executive director for Binx Health and Genomic Vision.

QuantuMDx said its CEO and Cofounder Elaine Warburton will move into the role of non-executive director and continue to support QuantuMDx in an ambassadorial role, including with key strategic projects. John Burn will step back as chairman, a role he had undertaken upon the company's inception in 2008, and become vice-chairman of the board of directors.

Jan 24, 2020

Guardant Health: Kumud Kalia

Guardant Health has appointed Kumud Kalia as its new chief information officer. In the role, he will lead the company's enterprise applications, information technology, and security teams. Kalia was most recently chief information and technology officer at Cylance, and previously served the same role at Akamai Technologies. He received Computerworld's "best in class" recognition among its 100 premier information technology leaders and has led teams that have won CIO100, CTO25, and other industry awards. He holds an honors degree in electronic engineering from Bangor University, is a chartered engineer, and is a fellow of both the Institution of Engineering and Technology and the British Computer Society.

Jan 23, 2020

Agilent Technologies: Mark Doak, Padriag McDonnell

Agilent Technologies said this week that Mark Doak will retire as senior VP of the firm and president of Agilent CrossLab Group, effective May 1, 2020. Agilent has named Padraig McDonnell, currently VP and general manager of the firm's chemistries and supplies division, to succeed Doak. McDonnell has served in various roles at Agilent for 22 years.  

Jan 21, 2020

Zymergen: Jay Flatley

Jay Flatley has joined the board of directors of Zymergen, serving as lead independent director. He is the chairman of the board of Illumina. From 1999 until 2016, Flatley was the CEO of Illumina, and until the end of 2019, he was the company's executive chairman.

Jan 21, 2020

GenMark Diagnostics: James McNally

GenMark Diagnostics said that on Jan. 9, it notified James McNally, its senior vice president of marketing and business development, that his employment with the firm would cease on Jan. 10.

In a filing with the US Securities and Exchange Commission, GenMark also said that on Jan. 14, it entered into a separation agreement and general release with McNally. In accordance with the agreement, McNally is entitled to benefits, including a gross lump sum payment equal to six months of his base salary in effect as of the separation date; an amount equal to McNally’s target bonus percentage under the firm's 2019 bonus plan multiplied by a percentage tied to the achievement of the company-level performance targets under the plan; and an aggregate of 35,702 restricted stock units held by McNally as of the separation date.

Jan 21, 2020

Qlucore: Johan Thiel and Boel Sundvall

Qlucore has named Johan Thiel and Boel Sundvall to its board of directors. Thiel is a longtime entrepreneur who served for six years as CEO of MIPS, a Swedish company known for making a "brain protection system" for bicycling and snowboarding helmets that reduces rotational forces that often lead to concussions. Sundvall comes from a background in corporate finance, investor relations, and communications, including with MIPS.  

Jan 15, 2020

Tempus: Ari Caroline, Iker Huerga

Tempus has hired Ari Caroline as senior VP of health strategy and Iker Huerga as VP of data engineering and strategy. Both founded healthcare artificial intelligence firm Da'At AI, an early-stage startup that Tempus recently acquired the entire team of. Prior to launching Da'At, Caroline was chief analytics officer at Memorial Sloan-Kettering Cancer Center in New York, while Huerga served as director of engineering and applied machine learning for MSK.

Jan 15, 2020

Illumina: Jay Flatley

Jay Flatley has become chairman of the board of directors at Illumina. Until the end of 2019, he was executive chairman, and from 1999 until mid-2016, he was Illumina's CEO. Previously, he was president and CEO of Molecular Dynamics, now part of GE Healthcare. Before that, he was VP of engineering and strategic planning at Plexus Computers, executive VP at Manning Technologies, and held various positions at Spectra Physics.

Jan 14, 2020

Myriad Genetics: Thomas Slavin

Thomas Slavin will be senior VP of medical affairs at Myriad Genetics' oncology division. Starting March 2, he will report to Nicole Lambert, president of Myriad Oncology, and be in charge of Myriad's portfolio of molecular and companion diagnostic products and services for oncology. Slavin is board certified in clincial genetics, medical diagnostics, and pediatrics, and most recently was an assistant professor in City of Hope National Medical Center's medical oncology & therapeutics research and population sciences division. 

Jan 13, 2020

T2 Biosystems: Tony Pare

T2 Biosystems has promoted Tony Pare to the newly created position of chief commercial officer, effective immediately. Pare previously served as vice president and general manager of T2 Biosystems' international business. Prior to that, he held senior business development positions at Haemonetics and Hemanext.

Jan 13, 2020

Spartan Bioscience: Dirk Sibbing; Gilles Montalescot; Marco Valgimigli; Davide Capodanno

Spartan Bioscience has establishd a scientific advisory board in Europe. The members are Dirk Sibbing, an inverventional cardiologist and professor of cardiology at Ludwig-Miximilians University in Munich; Gilles Montalescot, a professor of cardiology at the University of Paris VI, and director of the cardiac care unit at Pitié-Salpêtrière Hospital, Paris; Marco Valgimigli, associate professor of cardiology and senior interventional cardiology at Inselspital Universitätsspital in Bern, Switzerland; and Davide Capodanno, associate professor of cardiology at the University of Catania, Italy, and interventional cardiologist, Azienda ""Policlinico-Vittorio Emanuele" in Catania. The company added that a North American team will be announced in March at the American College of Cardiology conference. 

 

A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.

Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.

Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.

In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.